ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expression were studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma. Materials and Methods Seventy-two patients were enrolled in this study. Polymerase chain reaction amplification and direct sequencing were used for mutation analysis. ALK and MYCN amplifications were detected by fluorescence in situ hybridization. Protein expression was evaluated by immunohistochemical (IHC) staining. Results ALK mutation was found in only two patients (4.1%); ALK amplification was not detected. ALK positivity, loss of nuclear ATRX protein, TERT positivity by IHC were detected in 40 (55.6%), nine (13.0%), and 42 (59.2%) patients, respectively. The incidence of ALK expression increased in accordance with increasing tumor stage (p=0.001) and risk group (p < 0.001). The relapse rate was significantly higher in ALK+ patients compared to that of other patients (47.5% vs. 11.3%, p=0.007). However, there was no significant difference in relapse rate when the survival analysis was confined to the high-risk patients. Conclusion Although ALKmutation was rare and no amplification was observed, ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma. ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.
Abstract
Purpose In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expression were studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma. Materials and Methods Seventy-two patients were enrolled in this study. Polymerase chain reaction amplification and direct sequencing were used for mutation analysis. ALK and MYCN amplifications were detected by fluorescence in situ hybridization. Protein expression was evaluated by immunohistochemical (IHC) staining. Results ALK mutation was found in only two patients (4.1%); ALK amplification was not detected. ALK positivity, loss of nuclear ATRX protein, TERT positivity by IHC were detected in 40 (55.6%), nine (13.0%), and 42 (59.2%) patients, respectively. The incidence of ALK expression increased in accordance with increasing tumor stage (p=0.001) and risk group (p < 0.001). The relapse rate was significantly higher in ALK+ patients compared to that of other patients (47.5% vs. 11.3%, p=0.007). However, there was no significant difference in relapse rate when the survival analysis was confined to the high-risk patients. Conclusion Although ALKmutation was rare and no amplification was observed, ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma. ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.
참고문헌 (30)
- Maris JM, "Neuroblastoma", Lancet, 369, pp.2106~2120 (2007)[DOI]
- Ambros PF, "International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee", Br J Cancer, 100, pp.1471~1482 (2009)[DOI]
- Janoueix-Lerosey I, "Overall genomic pattern is a predictor of outcome in neuroblastoma", J Clin Oncol, 27, pp.1026~1033 (2009)[DOI]
- Ladenstein R, "Prognostic significance of DNA di-tetraploidy in neuroblastoma", Med Pediatr Oncol, 36, pp.83~92 (2001)[DOI]
- Stallings RL, "Are chromosomal imbalances important in cancer?", Trends Genet, 23, pp.278~283 (2007)[DOI]
- Schleiermacher G, "Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project", Br J Cancer, 107, pp.1418~1422 (2012)[DOI]
- Chen Y, "Oncogenic mutations of ALK kinase in neuroblastoma", Nature, 455, pp.971~974 (2008)[DOI]
- George RE, "Activating mutations in ALK provide a therapeutic target in neuroblastoma", Nature, 455, pp.975~978 (2008)[DOI]
- Janoueix-Lerosey I, "Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma", Nature, 455, pp.967~970 (2008)[DOI]
- Mosse YP, "Identification of ALK as a major familial neuroblastoma predisposition gene", Nature, 455, pp.930~935 (2008)[DOI]
- Miyake I, "Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines", Oncogene, 21, pp.5823~5834 (2002)[DOI]
- Osajima-Hakomori Y, "Biological role of anaplastic lymphoma kinase in neuroblastoma", Am J Pathol, 167, pp.213~222 (2005)[DOI]
- Blackburn EH, "Telomeres and telomerase: the means to the end (Nobel lecture)", Angew Chem Int Ed Engl, 49, pp.7405~7421 (2010)[DOI]
- Cheung NK, "Association of age at diagnosis and genetic mutations in patients with neuroblastoma", JAMA, 307, pp.1062~1071 (2012)[DOI]
- Peifer M, "Telomerase activation by genomic rearrangements in high-risk neuroblastoma", Nature, 526, pp.700~704 (2015)[DOI]
- Valentijn LJ, "TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors", Nat Genet, 47, pp.1411~1414 (2015)[DOI]
- Maris JM, "The biologic basis for neuroblastoma heterogeneity and risk stratification", Curr Opin Pediatr, 17, pp.7~13 (2005)[DOI]
- Subramaniam MM, "Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas", Hum Pathol, 40, pp.1638~1642 (2009)[DOI]
- Bresler SC, "Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma", Sci Transl Med, 3, pp.108ra14~ (2011)
- Infarinato NR, "The ALK", ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma, 2016, pp.6, 96~107
- Palmer RH, "Anaplastic lymphoma kinase: signalling in development and disease", Biochem J, 420, pp.345~361 (2009)[DOI]
- Bonvini P, "High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma", Br J Cancer, 109, pp.3084~3091 (2013)[DOI]
- Gasparini P, "Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma", Oncotarget, 7, pp.58903~58914 (2016)
- Passoni L, "Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients", Cancer Res, 69, pp.7338~7346 (2009)[DOI]
- Schulte JH, "High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma", Clin Cancer Res, 17, pp.5082~5092 (2011)[DOI]
- Duijkers FA, "High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome", Am J Pathol, 180, pp.1223~1231 (2012)[DOI]
- Schonherr C, "Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells", Oncogene, 31, pp.5193~5200 (2012)[DOI]
- Umapathy G, "The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma", Sci Signal, 7, pp.ra102~ (2014)[DOI]
- Ohali A, "Telomere length is a prognostic factor in neuroblastoma", Cancer, 107, pp.1391~1399 (2006)[DOI]
- Lovejoy CA, "Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway", PLoS Genet, 8, pp.e1002772~ (2012)[DOI]